Executive Intelligence

Eric Lefkofsky

Founder

Eric Lefkofsky is listed as a founder of Tempus AI based in United States on Brel Digital’s verified company intelligence record.

In this profile

Quick Facts

  • Role Founder
  • Company Tempus AI
  • Country United States
  • Industry AI in Healthcare
  • Founded 2015
  • Known For Tempus AI sits at the intersection of clinical data infrastructure and pharmaceutical R&D partnerships, making it…
  • Status Active
  • Last Reviewed Jul 2026

Executive Summary

Eric Lefkofsky appears in Brel Digital’s verified company_founders attribution for Tempus AI based in United States in the Healthcare sector. This profile records that founder relationship using sources already on file for the company. Personal biography details that are not evidenced in those sources are omitted. Company context (from the verified Tempus AI profile): Chicago-based precision medicine company applying AI and multimodal data to oncology and clinical decision support Why the company matters (verified company field): Tempus AI sits at the intersection of clinical data infrastructure and pharmaceutical R&D partnerships, making it a reference point for how AI-driven precision medicine moves from research datasets into multi-year drug-development collaborations with major pharma companies. Official company website on file: https://www.tempus.com. Readers should consult that site and the Sources section for primary evidence. Brel Digital does not invent prior roles, education, funding history, or awards for founder profiles. Where additional verified public leadership pages become available, this profile should be deepened in a subsequent editorial review.

Career Timeline

Verified company milestones linked to this executive’s organization.

  1. 2015 Company founded

    Tempus AI was founded in 2015 per the company profile source on file.

    Source
  2. 2015 Development

    2015: Tempus founded in Chicago by Eric Lefkofsky, who serves as chief executive officer.

    Source
  3. 2025 Acquisition

    August 22, 2025: Tempus announced the acquisition of Paige, a digital pathology company, for $81.25 million.

    Source
  4. 2026 Development

    March 3, 2026: Tempus announced a multi-year strategic collaboration agreement with Merck to accelerate AI-driven precision medicine through Tempus Lens and related capabilities.

    Source

Connected Company

Connected Products

Connected Reports

Connected Insights

Industry Intelligence

Eric Lefkofsky appears in Brel Digital’s verified company_founders attribution for Tempus AI based in United States in the Healthcare sector. This profile records that founder relationship using sources already on file for the company. Personal biography details that are not evidenced in those sources are omitted.

Company context (from the verified Tempus AI profile): Chicago-based precision medicine company applying AI and multimodal data to oncology and clinical decision support

Why the company matters (verified company field): Tempus AI sits at the intersection of clinical data infrastructure and pharmaceutical R&D partnerships, making it a reference point for how AI-driven precision medicine moves from research datasets into multi-year drug-development collaborations with major pharma companies.

Official company website on file: https://www.tempus.com. Readers should consult that site and the Sources section for primary evidence.

Brel Digital does not invent prior roles, education, funding history, or awards for founder profiles. Where additional verified public leadership pages become available, this profile should be deepened in a subsequent editorial review.

Sources and references

This article draws on publicly available company information, official websites, filings, interviews, announcements, and other cited sources. Information may change over time.

The AI Brief

Founder and company intelligence, weekly.

Subscribe